1![Functional disassociation of the central and peripheral fatty acid amide signaling systems Benjamin F. Cravatt*†, Alan Saghatelian*, Edward G. Hawkins*, Angela B. Clement*, Michael H. Bracey*, and Aron H. Lichtman‡ * Functional disassociation of the central and peripheral fatty acid amide signaling systems Benjamin F. Cravatt*†, Alan Saghatelian*, Edward G. Hawkins*, Angela B. Clement*, Michael H. Bracey*, and Aron H. Lichtman‡ *](https://www.pdfsearch.io/img/c60e38a3ea62b2c7afaf41ccc8485526.jpg) | Add to Reading ListSource URL: www.scripps.eduLanguage: English - Date: 2008-05-12 15:27:36
|
---|
2![doi:S1367 doi:S1367](https://www.pdfsearch.io/img/03c982a8d1f86fae66dbe31408c84f02.jpg) | Add to Reading ListSource URL: www.scripps.eduLanguage: English - Date: 2008-05-12 15:27:37
|
---|
3![Biochemistry 1999, 38, 14125 Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism† Biochemistry 1999, 38, 14125 Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism†](https://www.pdfsearch.io/img/7f1ec70678f7bc49b288b045884bed04.jpg) | Add to Reading ListSource URL: www.scripps.eduLanguage: English - Date: 2008-05-12 15:27:39
|
---|
4![SPECIAL AUTHORIZATION REQUEST DPP-4/SGLT2 INHIBITORS Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – PRESCRIBER INFORMATION SPECIAL AUTHORIZATION REQUEST DPP-4/SGLT2 INHIBITORS Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – PRESCRIBER INFORMATION](https://www.pdfsearch.io/img/2996eff068df140a59996c868b576bf7.jpg) | Add to Reading ListSource URL: www.gov.pe.caLanguage: English - Date: 2016-02-10 09:11:30
|
---|
5![Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES](https://www.pdfsearch.io/img/8d8be0e94a7c358f67b294f43a365958.jpg) | Add to Reading ListSource URL: poisoncontrol.utah.eduLanguage: English - Date: 2016-06-02 15:25:44
|
---|
6![Repeat in 2 to 5 years: sorafenib 200 mg cipla IV: 0.2 to 0.5 mg 3 to 4 hours. Don’t stop using the drug in question. Alprazolam may be recommended as part of the type of interventions, services and hotlines. Protect y Repeat in 2 to 5 years: sorafenib 200 mg cipla IV: 0.2 to 0.5 mg 3 to 4 hours. Don’t stop using the drug in question. Alprazolam may be recommended as part of the type of interventions, services and hotlines. Protect y](https://www.pdfsearch.io/img/dc3a2c54444d48de07f47ba565afc8c9.jpg) | Add to Reading ListSource URL: milfordk12.orgLanguage: English - Date: 2016-08-19 10:20:15
|
---|
7![-441–448$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Copyright © 2004 by The American Society for Pharmacology and Experimental Therapeutics JPET 311:441–448, 2004 Vol. 311, No. -441–448$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Copyright © 2004 by The American Society for Pharmacology and Experimental Therapeutics JPET 311:441–448, 2004 Vol. 311, No.](https://www.pdfsearch.io/img/ccfaa0eb3bacbb97e5eb19757d9fa591.jpg) | Add to Reading ListSource URL: www.scripps.eduLanguage: English - Date: 2008-05-12 15:27:36
|
---|
8![what is sorafenib. sorafenib tyrosine kinase sorafenib sunitinib everolimus. sorafenib rad001 tipifarnib sorafenib sorafenib bayer sorafenib patient comments. sorafenib dosage. il-2 and sorafenib versus sorafenib trial p what is sorafenib. sorafenib tyrosine kinase sorafenib sunitinib everolimus. sorafenib rad001 tipifarnib sorafenib sorafenib bayer sorafenib patient comments. sorafenib dosage. il-2 and sorafenib versus sorafenib trial p](https://www.pdfsearch.io/img/1278df6e31393412772b1738d484e06c.jpg) | Add to Reading ListSource URL: observantnomad.comLanguage: English - Date: 2016-08-18 20:00:51
|
---|
9![Supplementary Material to Beyer-Westendorf et al. “Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry” (Thromb Haemost 2015; 113.6) Supplementary Material to Beyer-Westendorf et al. “Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry” (Thromb Haemost 2015; 113.6)](https://www.pdfsearch.io/img/9556cda4ecd60f06a4b49e85405fe3f4.jpg) | Add to Reading ListSource URL: th.schattauer.deLanguage: English - Date: 2015-03-05 03:09:54
|
---|
10![gout drug interaction indocin colchincine. is indocin safe indocin and adverse effects. the drug indocin causes fatty liver indocin indocin for migraine indomethacin indocin no prescription indocin. indocin er gout drug interaction indocin colchincine. is indocin safe indocin and adverse effects. the drug indocin causes fatty liver indocin indocin for migraine indomethacin indocin no prescription indocin. indocin er](https://www.pdfsearch.io/img/381e361177b9d8b436926bad0192dce3.jpg) | Add to Reading ListSource URL: rivervest.comLanguage: English - Date: 2015-07-20 10:33:24
|
---|